Surgery & Anesthesia · 1983
Pulse oximetry enters routine clinical monitoring
For most of the twentieth century, a patient's arterial oxygen saturation during surgery was a matter of clinical inference. Anesthesiologists watched for cyanosis, but visible discoloration of mucous membranes does not appear reliably until saturation has fallen below roughly 85 percent, well into territory where organ injury can be occurring. Arterial blood gases provided precise measurements but required needle puncture, laboratory processing, and several minutes of delay. In the interval between a sample draw and its result, a patient could sustain hypoxic brain injury without triggering any continuous alarm.
Takuo Aoyagi, an engineer at Nihon Kohden in Japan, described the principle of pulse oximetry in 1974. He recognized that the pulsatile component of the photoplethysmographic signal could isolate arterial blood from tissue background, and that the ratio of light absorption at red and infrared wavelengths in that pulsatile fraction correlated with oxyhemoglobin saturation. The insight was elegant, but translating it into a reliable clinical instrument took nearly a decade of engineering work to overcome noise from patient movement, poor peripheral perfusion, and ambient light interference.
The Nellcor N-100, introduced in 1983, was the device that brought the technique into operating rooms at scale. William New, an anesthesiologist at Stanford, co-founded Nellcor specifically to commercialize continuous oximetry for clinical use, and the N-100 was compact and reliable enough for routine OR installation. Within two to three years of its introduction, continuous SpO2 monitoring had become standard equipment in most American operating rooms, a speed of adoption unusual for monitoring technology.
Clinical impact arrived against a backdrop of simultaneous changes. Anesthesia-related hypoxic deaths fell sharply in the late 1980s, but rigorous attribution is complicated. Capnography was being adopted at the same time, anesthetic agents were improving, and professional training standards were tightening. The Harvard Medical School affiliated hospitals adopted minimum monitoring standards in 1986, mandating both pulse oximetry and capnography for all general anesthesia; other academic centers and ultimately national anesthesiology societies followed. Whether the oximeter alone drove the mortality decline, or whether it was one component of a broader safety package, remains a subject of discussion among anesthesiologists.
Pulse oximeters spread well beyond the operating room. They became fixtures in emergency departments, intensive care units, post-anesthesia care units, and eventually general wards. Home oximeters became widely available to outpatients managing chronic lung disease or heart failure. During the COVID-19 pandemic, home pulse oximetry took on a specific clinical function: identifying patients with silent hypoxemia who reported mild symptoms, enabling earlier triage decisions. Aoyagi's 1974 insight, refined through Japanese and American engineering and commercialized in the early 1980s, runs through virtually every patient monitoring encounter in modern practice.
Key People
- Takuo Aoyagi — Nihon Kohden engineer who derived the two-wavelength pulse oximetry principle in 1974
- William New — Anesthesiologist who co-founded Nellcor and commercialized the first clinical oximeter
- Yoshiyuki Shimada — Japanese anesthesiologist who conducted early clinical validation of pulse oximetry
J Biomed Opt, 2024 (narrative history)
Related landmarks
- 1985 · First Laparoscopic Cholecystectomy (Surgery & Anesthesia)
- 1978 · Ciclosporin in solid-organ transplantation (Calne) (Surgery & Anesthesia)
- 1968 · Coronary Artery Bypass Grafting (CABG) (Surgery & Anesthesia)
- 1967 · First Human Heart Transplant (Surgery & Anesthesia)